Research

Gene network linked to Type 2 diabetes

Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.

Studies by Andrew Glazer, PhD, Giovanni Davogustto, MD, and colleagues found that genetic testing with information from electronic health records can reveal undiagnosed heart rhythm disorders.

Studies combine genetic testing, electronic health records to find undiagnosed diseases

Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations.

Calculating risk for uterine fibroids

Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

VUMC faculty members attending the meeting of the American Society for Clinical Investigation included, from left, Wesley Ely, MD, MPH, Patrick Hu, MD, PhD, Lorraine Ware, MD, Kimryn Rathmell, MD, PhD, Consuelo Wilkins, MD, MSCI, Christopher Williams, MD, PhD, Lori Jordan, MD, PhD, Natasha Halasa, MD, MPH, ASCI Council Member Julie Bastarache, MD, Eric Tkaczyk, MD, PhD, and James Crowe Jr., MD.

VUMC a national leader in physician-scientist training

Physician-scientists from Vanderbilt University Medical Center were well represented at the recent annual meeting of the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP) and the American Physician-Scientist Association.

When science spills onto social media

Vanderbilt researchers report that social media posts can offer insights into how the public feels about genome editing, with stances varying across platforms and differing from those of academics and policy makers.

1 49 50 51 52 53 136